Literature DB >> 10694150

Bordetella pertussis surveillance in England and Wales: 1995-7.

P G Van Buynder1, D Owen, J E Vurdien, N J Andrews, R C Matthews, E Miller.   

Abstract

Available data sources on disease due to Bordetella pertussis, including notifications, hospital admissions, deaths, and an enhanced laboratory-based surveillance system commenced in January 1994, were reviewed for the period 1995-7. Pertussis notifications continued their approximately 3-year cycle although at historically reduced levels. A slight seasonal increase in late summer/early autumn existed over and above a relatively constant background rate. Over time, the proportion of pertussis cases in younger, unvaccinated children, and to a lesser extent, adolescents and young adults, is increasing. There is a continuing significant and underreported mortality associated with pertussis in the very young age group. Disease due to serotype 1,2 is on the increase despite persistent high vaccination levels and this serotype causes more severe disease. The provision of preventative antibiotics prior to disease onset reduced the severity of the disease but its use remains uncommon in England and Wales. While overall levels of pertussis notifications have declined in recent times, vaccination efficacy wanes with increasing age, and pertussis remains a significant cause of mortality and severe morbidity in the very young. This could be reduced by timely booster vaccination and increased recognition of mild disease in older cases followed by early antibiotic therapy for the very young household contacts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10694150      PMCID: PMC2810773          DOI: 10.1017/s0950268899003052

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  26 in total

1.  Hypertrophic pyloric stenosis caused by erythromycin.

Authors:  J Hoey
Journal:  CMAJ       Date:  2000-04-18       Impact factor: 8.262

2.  Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.

Authors:  N K Fry; S Neal; T G Harrison; E Miller; R Matthews; R C George
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

3.  Perhaps it is not time to switch from whole cell to acellular pertussis vaccine.

Authors:  D Elliman; H Bedford
Journal:  BMJ       Date:  2000-08-12

4.  Pertussis immunisation.

Authors:  Abi Berger
Journal:  BMJ       Date:  2003-04-19

5.  Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan.

Authors:  Atsuko Kodama; Kazunari Kamachi; Yoshinobu Horiuchi; Toshifumi Konda; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

6.  Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.

Authors:  Hans O Hallander; Abdolreza Advani; Declan Donnelly; Lennart Gustafsson; Rose-Marie Carlsson
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

7.  Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type.

Authors:  David J Litt; Shona E Neal; Norman K Fry
Journal:  J Clin Microbiol       Date:  2009-01-21       Impact factor: 5.948

8.  Factors associated with immunisation coverage and timeliness in New Zealand.

Authors:  Cameron C Grant; Nikki M Turner; Deon G York; Felicity Goodyear-Smith; Helen A Petousis-Harris
Journal:  Br J Gen Pract       Date:  2010-03       Impact factor: 5.386

9.  The distribution over time of costs and social net benefits for pertussis immunization programs.

Authors:  Dorota Zdanowska Girard
Journal:  Int J Health Care Finance Econ       Date:  2009-03-18

10.  Severe and unrecognised: pertussis in UK infants.

Authors:  N S Crowcroft; R Booy; T Harrison; L Spicer; J Britto; Q Mok; P Heath; I Murdoch; M Zambon; R George; E Miller
Journal:  Arch Dis Child       Date:  2003-09       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.